Plain-English translation of NCT05150691 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This study is testing a new medication called to treat advanced cancers that have spread or cannot be surgically removed, especially those with a protein marker called HER2. The trial will first find the right dose and then test whether the medication is safe and whether it helps shrink tumors.
Many patients with advanced solid cancers have limited treatment options, especially if their cancer expresses HER2. This medication is being studied because it may offer a new way to target and fight these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You would receive an infusion or injection of the medication once every three weeks in treatment cycles. The study has two parts: first, researchers will test different dose levels to find the safest and most effective dose; then, more patients will receive the chosen dose to confirm it works and explore how well it controls the cancer. You will have regular blood tests, imaging scans, and heart function tests throughout the trial to monitor your safety and how you are responding.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States